Showing results (21-30 of 86) with videos related to
Sort By:
Pageof 9
Journal of Clinical Pathology|June 29, 2021
Gene of the month: lymphocyte-activation gene 3 (LAG-3)Mark P Lythgoe, Daniel Si Kit Liu, Nicola E Annels, et al.JAMA Network Open|June 10, 2022
Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019Mark P Lythgoe, Aakash Desai, Bishal Gyawali, et al.Cancers|August 27, 2021
Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine NeoplasiaRebecca Abdelmalak, Mark P Lythgoe, Joanne Evans, et al.The Lancet. Oncology|March 29, 2023
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following BrexitMark P Lythgoe, Jonathan Krell, Mark Bower, et al.Journal of Cancer Policy|November 2, 2023
Starting and stopping cancer drugs: The need for randomized trialsDavid J Benjamin, Vinay PrasadFrontiers in Immunology|September 7, 2023
Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapyDavid J Benjamin, Robert HsuFrontiers in Oncology|December 18, 2023
A narrative review of antibody-drug conjugates in <i>EGFR</i>-mutated non-small cell lung cancerRobert Hsu, David J BenjaminCancers|November 27, 2021
Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder CancerDavid J Benjamin, Yung LyouEuropean Journal of Cancer (Oxford, England : 1990)|October 5, 2024
Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancerDavid J Benjamin, Vinay PrasadCancer Investigation|October 5, 2022
Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic Malignancies from 2006 to 2020Ryan S Chiang, Aakash Desai, Michael J Glover, et al.Pageof 9